PsychoGenics Inc.
This article was originally published in Start Up
Executive Summary
Parly as a result of lack of predictable behavioral models, many CNS drugs fail in late-stage clinical trials. Formed three years ago, PsychoGenics seeks to offer better predictive models for CNS drug discovery. The company has improved behavioral tests, combined with bioinformatics, which produce more reliable preclinical test results for pharma and biotech clients. Eventually it hopes to enter the therapeutic market with its own drugs.